<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04205799</url>
  </required_header>
  <id_info>
    <org_study_id>2019-002184-97</org_study_id>
    <nct_id>NCT04205799</nct_id>
  </id_info>
  <brief_title>Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure</brief_title>
  <acronym>CABOCOL-01</acronym>
  <official_title>A Phase II Study Assessing Safety and Efficacy of Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess efficacy and safety of cabozantinib in monotherapy in advanced/metastatic cervical
      cancer (CC) after failure of platinum-based regimen treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of cabozantinib: proportion of patients with disease control rate</measure>
    <time_frame>3 months after cabozantinib treatment initiation.</time_frame>
    <description>Efficacy assessed by the proportion of patients with disease control rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of cabozantinib: proportion of patients with clinical gastro-intestinal (GI) perforation/fistula, GI-vaginal fistula and genito-urinary (GU) fistula events grade ≥ 2 (NCI CTCAE v 5.0)</measure>
    <time_frame>toxicities occurring up to 1 month after the end of treatment</time_frame>
    <description>Safety assessed by the proportion of patients with clinical gastro-intestinal (GI) perforation/fistula, GI-vaginal fistula and genito-urinary (GU) fistula events grade ≥ 2 (NCI CTCAE v 5.0)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response (RECIST v1.1 criteria)</measure>
    <time_frame>At the end of cycle 3,6,9... (each cycle is 28 days) through study completion, an average of 1 year</time_frame>
    <description>Objective response rate defined as the percentage of patients who have achieved complete response or partial response with RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>At the end of cycle 3,6,9... (each cycle is 28 days) through study completion, an average of 1 follow-up year</time_frame>
    <description>Progression-free survival, defined as the time between initiation of cabozantinib treatment and progression (RECIST 1.1 criteria) or death of any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>through study completion, an average of 1 follow-up year</time_frame>
    <description>Overall survival, defined as the time between initiation of cabozantinib treatment and death of whatever cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of cabozantinib</measure>
    <time_frame>every cycle of treatment (each cycle is 28 days) through study completion, an average of 1 follow-up year</time_frame>
    <description>Toxicities evaluated according to NCI CTCAE v5.0 criteria, in terms of kind, grade, time of onset, reversibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment Quality-of-life of patients assessed by EORTC QLQ-C30 /CX24 questionnaire</measure>
    <time_frame>At Day 15 of cycle 2 (each cycle is 28 days) and every 3 cycles of treatment ((every 12 weeks)) an average of 1 follow-up year</time_frame>
    <description>Scores of Quality-of-life according to French versions of the self-administered standardized validated questionnaire: EORTC QLQ-C30 with CX24</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Advanced/Metastatic Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>CABOZANTINIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabozantinib</intervention_name>
    <description>Cabozantinib will be administered at the daily dose of 60 mg given orally in a 4-week cycle. It will be continued without interruption until disease progression or discontinuation for any cause.</description>
    <arm_group_label>CABOZANTINIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female 18 years of age or older

          -  Histologically confirmed recurrent unresectable or metastatic cervix carcinoma with
             squamous cell, adenocarcinoma or adenosquamous histology - - Patient may have received
             at least one prior chemotherapy regimen of platinum-based chemotherapy for recurrence
             or metastatic disease.

          -  Cisplatin given in combination with radiation for a localized disease does not count
             as a prior chemotherapy.

          -  Prior treatment for advanced/metastatic disease with bevacizumab is allowed.

          -  Prior treatments with immune checkpoint inhibitors are allowed. - ECOG performance
             status 0-2 - Measurable disease per RECIST 1.1

          -  The subject must have recovered to baseline or CTCAE v.5.0 (Common Terminology
             Criteria for Adverse Events, version 5.0) ≤ Grade 1 from clinical toxicities related
             to any prior treatments, i.e chemotherapy or pelvis radiation unless AE(s) are
             clinically non-significant (for example alopecia)

          -  Adequate organ and marrow function, defined as follows, based upon laboratory tests
             performed within 7 days before inclusion:

               -  Absolute neutrophil count (ANC) ≥ 1000/mm3 (≥ 1.0 GI/L)

               -  Platelets ≥ 100,000/mm3 (≥ 100 GI/L)

               -  Hemoglobin ≥ 10 g/dL (≥ 100 g/L) (red blood cell transfusion is allowed)

               -  Total bilirubin ≤ 1.5 fold the upper limit of normal (for subjects with Gilbert's
                  disease, ≤ 3 mg/dL or ≤ 51.3 μmol/L) o Serum albumin ≥ 3.0 g/dL (≥ 30 g/L)

               -  Calculated creatinine clearance ≥ 30 mL/min by the CKD-EPI method.

               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 3.0 x the
                  upper limit of normal

               -  Urine protein/creatinine ratio (UPCR) ≤ 1g/g (≤ 113.17 mg/mmol creatinine) or
                  24-hour urine protein &lt; 1 g

          -  Left-ventricular ejection fraction ≥ 50%

          -  Subjects affiliated to an appropriate social security system

          -  Female subjects of childbearing potential must not be pregnant at screening and during
             treatment by Cabozantinib. Effective methods of contraception should be used
             throughout the course of treatment and for at least 4 months after the end of
             treatment. Sexually active fertile subjects and their partners must agree to use
             medically accepted barrier methods of contraception (e.g., male or female condom)
             during the study and 4 months after the last dose of study treatment, even if oral
             contraceptives are also used.

          -  Before patient registration, written informed consent must be given according to
             ICH/GCP, and national/local regulations.

        Exclusion Criteria:

          -  Clinically significant gastrointestinal abnormalities that may increase the risk for
             gastrointestinal bleeding and/or fistula including, but not limited to: Active peptic
             ulcer disease, inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease),
             or other gastrointestinal conditions with increased risk of perforation, history of
             abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess,
             gastro-intestinal obstruction Clinically significant gastrointestinal abnormalities
             that may affect absorption of investigational product including, but not limited to:
             malabsorption syndrome, major resection of the stomach or small bowel.

          -  Previously identified allergy or hypersensitivity to components of the study treatment
             formulations (Note: patients with rare hereditary problems of galactose intolerance,
             the Lapp lactase deficiency or glucose-galactose malabsorption should not take
             cabozantinib and are also excluded).

          -  History of any one or more of the following cardiovascular conditions within the past
             6 months: Cardiac angioplasty or stenting, myocardial infarction, unstable angina,
             coronary artery bypass surgery, symptomatic peripheral vascular disease, class III or
             IV congestive heart failure, as defined by the New York Heart Association (NYHA),
             serious cardiac arrythmias.

          -  Corrected QT interval (QTc) calculated by the Fridericia formula &gt; 500 msec within 28
             days before inclusion (see Annex for Fridericia formula). Note: if initial QTcF is
             found to be &gt; 500 msec, two additional ECGs separated by at least 3 minutes should be
             performed. If the average of these three consecutive results for QTcF is ≤ 500 msec,
             the subject meets eligibility in this regard.

          -  Uncontrolled hypertension defined as systolic blood pressure (SBP) of &gt; 150 mmHg or
             diastolic blood pressure (DBP) of &gt; 100 mmHg despite an optimal treatment.

          -  History of cerebrovascular accident including transient ischemic attack (TIA),
             symptomatic pulmonary embolism or untreated deep venous thrombosis (DVT) within the
             past 6 months. Note: Subjects with recent DVT or asymptomatic pulmonary embolism who
             have been treated with therapeutic anti-coagulating agents for at least 4 weeks are
             eligible.

          -  Major surgery or trauma within 28 days prior to first dose of investigational product
             and/or presence of any non-healing wound, fracture, or ulcer.

          -  Evidence of active bleeding or pathologic conditions that carry high risk of bleeding
             such as coagulopathy or tumor involving major vessels.

          -  At least 6 weeks must have elapsed between the last dose of pelvis palliative
             radiation and the first dose of cabozantinib or 2 weeks for other localization of
             palliative radiation

          -  Presence of brain metastases or epidural disease unless adequately treated with
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 3 months
             before inclusion. Eligible subjects must be neurologically asymptomatic and without
             corticosteroid treatment at the time of inclusion.

          -  Concomitant use of known strong CYP3A4 inhibitors or inducers.

          -  Patients with second primary cancer, except adequately treated non-melanoma skin
             cancer, or other solid tumors curatively treated with no evidence of disease for ≥ 3
             years

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule; those conditions
             should be discussed with the patient before registration in the trial

          -  Concurrent participation in any therapeutic clinical trial

          -  Patient deprived of liberty or placed under the authority of a tutor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elodie COQUAN, MD</last_name>
    <phone>(33)231455050</phone>
    <email>COQUE@baclesse.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie ABADIE LACOURTOISIE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie COQUAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar LAMBRET</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cyril Abdeddaim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier TREDAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique D'HONDT, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Sebastien FRENEL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut CURIE</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Coraline dubot, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emeline COLOMBA-BLAMEBLE, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>advanced/metastatic</keyword>
  <keyword>Cabozantinib</keyword>
  <keyword>platinum treatment failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

